samedi 10 octobre 2026
RechercherExplore
fr.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· September 30, 2026

Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?

View original at finance.yahoo.com
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? Both Moderna MRNA and BioNTech BNTX are leading biotechs at the forefront of messenger RNA (mRNA) technology…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Moderna and Merck plan to present detailed results at ESMO on Oct. 24 and engage with regulators regarding potential filings.

    60% confidence

  • Moderna and Merck are advancing intismeran across nine phase II and phase III studies spanning multiple tumor types, including NSCLC, bladder cancer and renal cell carcinoma.

    60% confidence

  • The intismeran plus Keytruda late-stage study in resected high-risk (Stage IIB-IV) melanoma met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival.

    60% confidence

Cité dans ces articles de Via News

Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Notre lecture des données ›
Signaux que nous suivons
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Tendances que nous surveillons ›
Là où les sources divergent
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,986
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,986 faits vérifiés avec la source5,365 documents sources archivés
Interrogez ces données → isubstrate.com